The investigators calculated UHR by dividing the first available serum uric acid concentration after admission, expressed in micromoles per liter, by the first available HDL-C concentration, expressed in millimoles per liter. Because the numerical value depends on the units used, the study’s estimated inflection point of 166.17 is specific to that unit convention. The cohort included 104 men and 200 women. Of the fractures, 214 were intertrochanteric and 90 were femoral neck fractures; 296 injuries resulted from falls, five from accidents and three from other mechanisms. Most patients received closed or open reduction and internal fixation, while smaller groups received hemiarthroplasty or total hip arthroplasty. Survival status after discharge was established through telephone contact with family members, allowing the researchers to examine whether a ratio derived from routine laboratory measurements was associated with subsequent mortality. As a retrospective observational study, however, it could not determine whether the ratio itself caused differences in outcomes.

When UHR was analyzed as a continuous variable in a conventional Cox proportional-hazards model, its unadjusted association with mortality was statistically significant at P = 0.0213. That relationship weakened after adjustment for age and sex and was no longer significant in the fully adjusted model, which also accounted for the age-adjusted Charlson Comorbidity Index, coronary heart disease, arrhythmia and dementia. The fully adjusted continuous-UHR result was P = 0.1413. Dividing participants into low, medium and high UHR tertiles produced a similar pattern: crude mortality was 18.00% in the low group, 30.69% in the middle group and 32.04% in the high group, but neither adjusted category comparison nor the adjusted trend test reached statistical significance. The fully adjusted hazard ratio for the high versus low tertile was 1.54, with a 95% confidence interval of 0.84–2.84 and P = 0.1624. These results therefore do not support describing UHR as an independent predictor under a linear or tertile-based parameterization.

Those conventional results motivated the researchers to examine whether a straight-line model was masking a different functional shape. Using restricted cubic splines for visual assessment and an exploratory two-piecewise Cox model, the team estimated an inflection point at a UHR of 166.17 under the study’s micromole-per-liter-to-millimole-per-liter convention. Below that value, each one-unit increase in UHR was associated with a hazard ratio for death of 1.01, with a 95% confidence interval of 1.00–1.03 and P = 0.0326. Above the inflection point, the estimated additional slope was effectively flat and not statistically significant, with P = 0.8050. A likelihood-ratio test comparing the single-slope and two-piecewise models favored the nonlinear specification, P = 0.037. The analysis therefore identified a possible association concentrated within the lower portion of the observed UHR range, rather than a consistent increase in mortality risk across the entire range.

The fitted shape should not be mistaken for proof of a biological threshold. “Plateau” is a description of the model’s estimated curve, not a demonstration that a specific mechanism switches on at 166.17. Nor does the flat slope above that point mean that patients with higher UHR have the same absolute mortality risk as those with low UHR. It means only that, within this dataset, additional increases above the estimated inflection point were not detectably associated with further increases in the modeled hazard. The threshold and both slopes were estimated from the same small cohort, creating scope for overfitting and optimism. For the fully adjusted continuous-UHR model there were approximately 11.7 deaths per regression parameter, while models using tertiles or two UHR slopes had approximately 10.3. Those conventional ratios do not capture the additional uncertainty introduced by choosing an inflection point from the same data.

Groups also differed in ways that complicate simple interpretations of the tertile results. The proportion of men increased from 18.00% in the low-UHR group to 37.62% in the middle group and 46.60% in the high group, although women still slightly outnumbered men in the highest group, 55 to 48. Fracture classification, prevalence of coronary heart disease, time to admission and surgical treatment also varied across tertiles. Time to admission followed a non-monotonic pattern—66.49, 190.73 and 83.06 hours from low to high UHR—so the difference cannot be interpreted as a dose-response relationship or as a consequence of UHR. The higher crude mortality in the highest tertile is compatible with a plateau above the estimated inflection point because a null slope above 166.17 means that additional increases within the higher range were not detectably associated with further risk. It does not erase differences accumulated across lower UHR values. Nevertheless, because the fully adjusted tertile comparison was not significant, UHR cannot be described as an independent predictor on the basis of these data.

UHR is attractive as a candidate marker because it combines two inexpensive measurements already obtained in routine care. The investigators noted that uric acid has been associated in prior research with adverse outcomes in cardiovascular disease, metabolic syndrome and chronic kidney disease, while HDL-C has been linked with vascular functions including anti-inflammatory and antioxidant activity and cholesterol reverse transport. The ratio was proposed as a possible combined indicator of metabolic and inflammatory disturbance accompanying hip fracture and therefore as a marker that might supplement conventional prognostic assessment. However, this study did not measure inflammasome activation, cytokines, oxidative injury or HDL function. Links involving oxidative stress, inflammation, endothelial dysfunction or reduced HDL-related antioxidant capacity remain possible biological explanations rather than demonstrated mechanisms in these patients.

Several limitations constrain how far the findings can be generalized. The cohort came from one trauma center and included 304 participants and 82 deaths, limiting statistical precision and generalizability. UHR was measured only once after admission for an acute fracture. Trauma, fasting status, hydration, renal function, medications and perioperative stress may alter uric acid or HDL-C, so the admission value may not represent a patient’s pre-fracture metabolic state. The analysis also could not adjudicate cardiovascular, infectious, malignant or other causes of death because only all-cause mortality was available. Residual confounding from lifestyle, medication use, renal function, frailty, sarcopenia and socioeconomic conditions remains possible. The study did not evaluate whether UHR adds information beyond established clinical, frailty, muscle, inflammatory or nutritional assessments, and it did not test whether adding the ratio would improve discrimination, calibration or clinical decision-making.

A value of 166.17 is therefore a cohort- and unit-specific estimated inflection point, not a validated clinical benchmark, and patients with values above it should not automatically receive intensified treatment on the basis of UHR alone. The researchers called for prospective multicenter studies to confirm the functional form of the association, repeat UHR measurements after the acute stress period, validate any threshold externally and determine whether UHR adds useful prognostic information beyond established measures. Until then, the result is best understood as hypothesis-generating evidence: an accessible candidate marker with an exploratory nonlinear signal, but no demonstrated independent predictive value for guiding care after hip fracture.

Subject of Research: Association between admission uric acid-to-HDL cholesterol ratio and long-term mortality in older adults after hip fracture surgery

Article Title: Admission uric acid to HDL-C ratio and long-term mortality after hip fracture in older adults: a retrospective cohort study

Article References: Han, S., Fu, Y.-H., Ke, C., & Zhang, B.-F. (2026). Admission uric acid to HDL-C ratio and long-term mortality after hip fracture in older adults: a retrospective cohort study. Frontiers in Medicine, 13, Article 1906596. https://doi.org/10.3389/fmed.2026.1906596

Image Credits: AI Generated

DOI: 10.3389/fmed.2026.1906596

Keywords: hip fracture, uric acid, HDL cholesterol, UHR, older adults, mortality, retrospective cohort, nonlinear association, survival analysis, prognostic biomarker, Admission, uric

The research, published in BMC Endocrine Disorders by Jiying Zhu and Tao Chen of the Department of Endocrinology and Metabolism at Longyan First Affiliated Hospital of Fujian Medical University, followed 726 patients with confirmed type 2 diabetes mellitus who were hospitalized at the institution between June 2022 and May 2025. All participants provided written informed consent, and the study received approval from the hospital’s ethics committee. The team set out to answer a deceptively simple question: among three widely used insulin resistance indices—the metabolic score for insulin resistance (METS-IR), the homeostasis model assessment of insulin resistance (HOMA-IR), and the serum uric acid-to-high-density lipoprotein cholesterol ratio (UHR)—which one best captures both the presence and the depth of metabolic syndrome in a population already burdened by diabetes?

The choice of these three indices reflects a broader shift in metabolic research. The gold standard for measuring insulin resistance, the euglycemic hyperinsulinemic clamp, is technically demanding, expensive, and impractical for routine clinical use. Surrogate markers have therefore proliferated. HOMA-IR, derived from fasting insulin and fasting plasma glucose, has dominated the field for decades but depends on reliable insulin assays and loses accuracy as beta-cell function declines—a particular problem in type 2 diabetes, where insulin secretion is often impaired. METS-IR, a newer composite score built from fasting glucose, body mass index, triglycerides, and height, sidesteps the need for insulin measurements altogether. UHR, the ratio of serum uric acid to HDL cholesterol, draws on two routinely measured analytes and captures an oxidative and lipid-metabolic dimension of insulin resistance that the other indices ignore.

Using a retrospective case design, the investigators ran a battery of statistical tests on the cohort. Correlation analysis first established whether the three indices moved in tandem with the individual components of metabolic syndrome—waist circumference, blood pressure, triglycerides, HDL cholesterol, and glycemic measures. Multivariable regression models then tested whether each index remained independently associated with metabolic syndrome after accounting for confounders, with variance inflation factors used to check for problematic collinearity between predictors. Finally, receiver operating characteristic (ROC) curves quantified how well each index discriminated between patients with and without the syndrome, and decision curve analysis (DCA) translated those statistical properties into a more clinically meaningful question: which index would deliver the greatest net benefit if actually deployed as a screening tool across a range of risk thresholds?

The results were strikingly consistent. After full multivariable adjustment, all three indices were independently associated with the occurrence of metabolic syndrome, each with a P value below 0.001. When the team applied a China Age-Sex-Ethnicity-Specific Metabolic Syndrome Severity score—a continuous metric designed to grade metabolic burden rather than merely flag it—the positive associations held firm. METS-IR showed a beta coefficient of 0.12 per unit (95% confidence interval 0.11 to 0.12), HOMA-IR a beta of 0.14 (95% CI 0.12 to 0.17), and UHR a beta of 0.14 (95% CI 0.13 to 0.15), all statistically significant. In plain terms, the higher a patient’s insulin resistance score, the more severe their metabolic syndrome, in a graded and quantifiable relationship rather than a threshold effect.

Discrimination told an even sharper story. METS-IR achieved an area under the ROC curve of 0.893 for identifying metabolic syndrome—the strongest of the three indices. An AUC approaching 0.9 is generally considered excellent, indicating that the score separates patients with the syndrome from those without it with high fidelity. The DeLong test, a formal statistical comparison of correlated ROC curves included in the study’s supplementary analyses, was used to confirm that differences in discriminative performance between the indices were meaningful rather than artifacts of sampling. For a metric that requires nothing more than a fasting blood draw and a few anthropometric measurements, that level of performance is notable.

Perhaps the most clinically consequential finding came from the decision curve analysis. ROC curves measure statistical discrimination, but they say little about what happens when a test is actually used to make decisions—which patients get intensified follow-up, which get lifestyle intervention, which get closer pharmacologic attention. DCA addresses this by calculating net benefit across a spectrum of threshold probabilities, weighing the cost of false positives against the cost of missed cases. Across a broad range of thresholds, METS-IR conferred the highest clinical net benefit of the three indices, suggesting that it is not merely the best statistical performer but the most useful practical screening instrument for real-world metabolic risk assessment in this population.

The study’s embrace of a continuous severity framework deserves particular attention. The China Age-Sex-Ethnicity-Specific severity scoring approach recognizes that metabolic risk is not distributed uniformly across a population: the same cluster of abnormalities may carry different prognostic weight depending on a patient’s age, sex, and ethnic background. Chinese cohorts, for example, tend to develop central obesity and metabolic complications at lower waist circumferences and body mass indices than many Western reference populations, and ethnicity-specific calibration helps correct for that. By converting the diagnosis into a graded score, the framework allows clinicians and researchers to track small but meaningful changes in metabolic burden over time—changes that a binary diagnosis would simply erase.

Why does this matter for the millions of people living with type 2 diabetes? Because metabolic syndrome in a diabetic patient is not a redundant label; it marks a substantially elevated risk of cardiovascular events, fatty liver disease, and chronic kidney disease, and it signals that the patient’s overall metabolic machinery is under strain beyond the glucose disorder itself. Insulin resistance sits at the mechanistic heart of this cluster: it drives hepatic fat accumulation, promotes very-low-density lipoprotein secretion, impairs vascular function, and links adipose tissue inflammation to systemic metabolic derangement. A cheap, reproducible index that tracks this underlying driver—and that correlates with the graded severity of the syndrome—gives clinicians a quantitative handle on risk that the current diagnostic checklist cannot provide.

The authors conclude that METS-IR is strongly associated with both the development and the severity of metabolic syndrome and plays a significant role in its risk assessment and clinical management. The study is not without the usual limits of a single-center retrospective design, and the findings will need validation in prospective, multi-ethnic cohorts before practice changes. But the direction of travel is clear. As medicine moves away from binary disease labels toward continuous, personalized measures of metabolic health, tools like METS-IR—simple enough to calculate in any clinic, yet powerful enough to grade the full spectrum of metabolic dysfunction—may become a routine part of how physicians judge and manage risk in patients with type 2 diabetes, in China and well beyond.

Subject of Research: Insulin resistance indices and metabolic syndrome severity in Chinese patients with type 2 diabetes

Article Title: The association between insulin resistance and the occurrence of metabolic syndrome in Chinese patients with type 2 diabetes, and the application of China Age-Sex-Ethnicity-Specific of Metabolic Syndrome Severity scoring

Article References: Zhu, J., & Chen, T. (2026). The association between insulin resistance and the occurrence of metabolic syndrome in Chinese patients with type 2 diabetes, and the application of China Age-Sex-Ethnicity-Specific of Metabolic Syndrome Severity scoring. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02580-9

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02580-9

Keywords: metabolic syndrome, insulin resistance, type 2 diabetes, METS-IR, HOMA-IR, UHR, metabolic syndrome severity score, ROC analysis, decision curve analysis, BMC Endocrine Disorders, China, cardiometabolic risk